Divi's Laboratories (DIVISLAB) Resumen de Acciones
Divi's Laboratories Limited se dedica a la fabricación y venta de ingredientes farmacéuticos activos (API) genéricos, productos intermedios y nutracéuticos en India, Norteamérica, Asia, Europa e internacionalmente. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 0/6 |
| Crecimiento futuro | 3/6 |
| Rendimiento pasado | 4/6 |
| Salud financiera | 5/6 |
| Dividendos | 4/6 |
DIVISLAB Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pharmaceuticals & Biotech opportunity
ST
Fair Value from
US$21.5364.4% infravalorado descuento intrínseco
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
Read full narrativeCompetidores de Divi's Laboratories Limited
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | ₹6,502.50 |
| Máximo en las últimas 52 semanas | ₹7,071.50 |
| Mínimo de 52 semanas | ₹5,636.50 |
| Beta | 0.19 |
| Cambio en 1 mes | 11.03% |
| Variación en 3 meses | 9.24% |
| Cambio de 1 año | 6.53% |
| Variación en 3 años | 97.60% |
| Variación en 5 años | 61.39% |
| Variación desde la OPV | 73,687.23% |
Noticias y actualizaciones recientes
DIVISLAB: Upcoming Board Review Will Support Bullish Long Term Outlook
Analysts have lifted their price target for Divi's Laboratories slightly, with fair value now seen around ₹8,620 versus about ₹8,554 earlier, reflecting updated assumptions for discount rate, revenue growth, profit margin and future P/E. What's in the News A board meeting is scheduled on Feb 11, 2026 to consider and approve unaudited standalone financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).
DIVISLAB: Elevated Future P/E Will Persist Despite Unchanged Fair Value Estimate
Analysts have maintained Divi's Laboratories' fair value estimate at ₹5,140 per share, with only small tweaks to assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together guide the latest price target narrative. What's in the News Board meeting scheduled for February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (Key Developments).
DIVISLAB: Upcoming Board Review And Fair Value Update Signal Constructive Outlook
Analysts have made a small upward adjustment to the fair value estimate for Divi's Laboratories to around ₹6,875, reflecting slightly updated assumptions on the discount rate, revenue growth, profit margins and future P/E. What's in the News Board meeting scheduled on February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).DIVISLAB: Rich Future P/E Will Persist Despite Softer Outlook After Results
Analysts have trimmed their price target on Divi's Laboratories from ₹5,290 to ₹5,140, reflecting updated assumptions around a slightly lower revenue growth outlook, a marginally higher profit margin, a modestly reduced future P/E multiple, and an adjusted discount rate. What's in the News A board meeting is scheduled for February 11, 2026 to review and approve unaudited standalone and consolidated financial results for the quarter ended December 31, 2025 (Key Developments).DIVISLAB: Upcoming Results Review Will Shape Balanced Long Term Outlook
Narrative Update on Divi's Laboratories The analyst price target for Divi's Laboratories has been adjusted slightly higher from about ₹6,823 to roughly ₹6,870, with analysts pointing to small refinements in assumptions around discount rate, revenue growth, profit margin and future P/E as the drivers of this change. What's in the News A board meeting is scheduled for February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).Recent updates
DIVISLAB: Upcoming Board Review Will Support Bullish Long Term Outlook
Analysts have lifted their price target for Divi's Laboratories slightly, with fair value now seen around ₹8,620 versus about ₹8,554 earlier, reflecting updated assumptions for discount rate, revenue growth, profit margin and future P/E. What's in the News A board meeting is scheduled on Feb 11, 2026 to consider and approve unaudited standalone financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).DIVISLAB: Elevated Future P/E Will Persist Despite Unchanged Fair Value Estimate
Analysts have maintained Divi's Laboratories' fair value estimate at ₹5,140 per share, with only small tweaks to assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together guide the latest price target narrative. What's in the News Board meeting scheduled for February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (Key Developments).DIVISLAB: Upcoming Board Review And Fair Value Update Signal Constructive Outlook
Analysts have made a small upward adjustment to the fair value estimate for Divi's Laboratories to around ₹6,875, reflecting slightly updated assumptions on the discount rate, revenue growth, profit margins and future P/E. What's in the News Board meeting scheduled on February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).DIVISLAB: Rich Future P/E Will Persist Despite Softer Outlook After Results
Analysts have trimmed their price target on Divi's Laboratories from ₹5,290 to ₹5,140, reflecting updated assumptions around a slightly lower revenue growth outlook, a marginally higher profit margin, a modestly reduced future P/E multiple, and an adjusted discount rate. What's in the News A board meeting is scheduled for February 11, 2026 to review and approve unaudited standalone and consolidated financial results for the quarter ended December 31, 2025 (Key Developments).DIVISLAB: Upcoming Results Review Will Shape Balanced Long Term Outlook
Narrative Update on Divi's Laboratories The analyst price target for Divi's Laboratories has been adjusted slightly higher from about ₹6,823 to roughly ₹6,870, with analysts pointing to small refinements in assumptions around discount rate, revenue growth, profit margin and future P/E as the drivers of this change. What's in the News A board meeting is scheduled for February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).DIVISLAB: Upcoming Results Review Will Support Bullish Long Term Outlook
Analysts have lifted their price target on Divi's Laboratories slightly to ₹6,823 from about ₹6,785, citing refreshed assumptions around discount rates, revenue growth, profit margin and future P/E that remain broadly in line with prior views. What's in the News A board meeting is scheduled for February 11, 2026, to review and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).DIVISLAB: Management Changes And Rich Future P/E Will Sustain Excessive Optimism
Analysts now cite slightly higher assumptions on growth, profitability and future P/E in their models for Divi's Laboratories, which feeds into an updated fair value estimate of ₹5,290, compared with the previous ₹5,035.89. What's in the News Board meeting scheduled for November 7, 2025, at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).DIVISLAB: Upcoming Board Review And Management Changes Will Support Bullish Outlook
Analysts have raised their price target for Divi's Laboratories from ₹7,750 to about ₹8,554, citing updated assumptions related to revenue growth, profit margins and future P/E levels in their models. What's in the News Board meeting scheduled on Nov 07, 2025 at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended Sep 30, 2025 (company filing).Earnings Not Telling The Story For Divi's Laboratories Limited (NSE:DIVISLAB)
Dec 30
DIVISLAB: Rising Profitability Expectations Will Mask Moderating Revenue And Justify Excessive Optimism
Analysts have raised their price target for Divi's Laboratories from ₹4,756 to ₹5,036, citing expectations of stronger profitability and a slightly richer future valuation multiple, despite moderating revenue growth assumptions. What's in the News Board meeting scheduled for November 7, 2025 at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).DIVISLAB: Upcoming Board Meeting And Leadership Review Will Shape Fair Outlook
Analysts have nudged their price target for Divi's Laboratories slightly higher, reflecting marginal improvements in discount rate assumptions and long term growth expectations that together support a fair value estimate of ₹6,785.10 per share. What's in the News Board meeting scheduled for November 7, 2025, at 10:30 IST to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).Divi's Laboratories (NSE:DIVISLAB) Seems To Use Debt Quite Sensibly
Dec 09DIVISLAB: Upcoming Board Decisions And Modest Earnings Improvements Will Shape Outlook
Analysts have raised their fair value estimate for Divi's Laboratories from ₹6,433 to ₹6,785, citing modest improvements in revenue growth and profit margin expectations. What's in the News A board meeting is scheduled for November 7, 2025, at 10:30 IST to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Key Developments).Investors Shouldn't Be Too Comfortable With Divi's Laboratories' (NSE:DIVISLAB) Earnings
Nov 15Divi's Laboratories Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Nov 11DIVISLAB: Upcoming Board Decisions And Modest Earnings Improvements Will Shape Outlook
Analysts have modestly increased their price target for Divi's Laboratories from ₹6,363 to ₹6,433, citing slight improvements in projected revenue growth and profit margins as the underlying factors. What's in the News Upcoming Board Meeting scheduled for November 7, 2025, at 10:30 AM IST.Divi's Laboratories Limited's (NSE:DIVISLAB) Share Price Could Signal Some Risk
Sep 06Custom Synthesis And Capacity Expansion Will Unlock Global Demand
With both the consensus price target and future P/E ratio for Divi's Laboratories remaining virtually unchanged, analysts signal stable valuation expectations, resulting in a steady fair value assessment at ₹6363. What's in the News Board meeting scheduled to consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2025.Divi's Laboratories Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 10Most Shareholders Will Probably Agree With Divi's Laboratories Limited's (NSE:DIVISLAB) CEO Compensation
Aug 05Here's What Analysts Are Forecasting For Divi's Laboratories Limited (NSE:DIVISLAB) After Its Yearly Results
Jul 17
Tactical Expansions And Innovation Could Offset Generic Pricing Pressures And Boost Profitability
Strategic investments in peptide synthesis and greenfield expansion enhance future revenue potential through capacity and product line growth.Rentabilidad de los accionistas
| DIVISLAB | IN Life Sciences | Mercado IN | |
|---|---|---|---|
| 7D | 2.2% | 2.6% | 0.4% |
| 1Y | 6.5% | 4.9% | 4.0% |
Rentabilidad vs. Industria: DIVISLAB superó a la industria Indian Life Sciences, que obtuvo un rendimiento del 4.9% el año pasado.
Rentabilidad vs. Mercado: DIVISLAB superó al mercado Indian, que obtuvo un rendimiento del 4% el año pasado.
Volatilidad de los precios
| DIVISLAB volatility | |
|---|---|
| DIVISLAB Average Weekly Movement | 3.1% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.7% |
Precio estable de las acciones: DIVISLAB no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado Indian.
Volatilidad a lo largo del tiempo: La volatilidad semanal de DIVISLAB (3%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1990 | 10,542 | Kiran Divi | www.divislabs.com |
Divi's Laboratories Limited se dedica a la fabricación y venta de ingredientes farmacéuticos activos genéricos (API), productos intermedios y nutracéuticos en India, Norteamérica, Asia, Europa e internacionalmente. La empresa también realiza servicios de fabricación por contrato de síntesis personalizada de API e intermedios; y suministra una gama de carotenoides, como betacaroteno, astaxantina, licopeno y cantaxantina, así como otras formas acabadas, incluida la luteína, y vitaminas a industrias de alimentación, suplementos dietéticos y fabricantes de piensos. También exporta sus productos.
Resumen de fundamentos de Divi's Laboratories Limited
| Estadísticas fundamentales de DIVISLAB | |
|---|---|
| Capitalización bursátil | ₹1.73t |
| Beneficios(TTM) | ₹24.79b |
| Ingresos (TTM) | ₹103.14b |
69.6x
Ratio precio-beneficio (PE)16.7x
Ratio precio-ventas (PS)¿Está DIVISLAB sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de DIVISLAB | |
|---|---|
| Ingresos | ₹103.14b |
| Coste de los ingresos | ₹39.55b |
| Beneficio bruto | ₹63.59b |
| Otros gastos | ₹38.80b |
| Beneficios | ₹24.79b |
Últimos beneficios comunicados
Dec 31, 2025
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 93.38 |
| Margen bruto | 61.65% |
| Margen de beneficio neto | 24.04% |
| Ratio deuda/patrimonio | 0.6% |
¿Cómo se ha desempeñado DIVISLAB a largo plazo?
Ver rendimiento histórico y comparativaDividendos
0.5%
Rentabilidad actual por dividendo36%
Ratio de pagosAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/03 08:30 |
| Precio de las acciones al final del día | 2026/04/30 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/03/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Divi's Laboratories Limited está cubierta por 57 analistas. 30 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Pranav Chawla | Ambit Capital |
| Prashant Nair | Ambit Capital |